Skip to content

Collegium Pharmaceutical

US · COLL #3535 by market cap Listed 2015
24.72 -0.49 -1.94%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 2.65 Cheap vs history 9th percentile
5-year average 4.14 · #46 of 69 in Drug Manufacturers - Specialty & Generic
P/E ratio 23.23 Expensive vs history 74th percentile
5-year average 11.57 · forward 12.59 · #14 of 26 in Drug Manufacturers - Specialty & Generic
P/S ratio 0.97 Cheap vs history 4th percentile
5-year average 1.75 · forward 0.93 · #21 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Collegium Pharmaceutical (COLL) 768.18M 22.68 2.59 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value37.88 Economic moatNone UncertaintyHigh

Trading 53.3% below Morningstar's fair value estimate.

Fair value

At face value, Collegium Pharmaceutical Inc looks inexpensive, following a substantial price decline over the past year. To account for the risk of a possible value trap, we have capped its rating at 3 stars. The stock currently trades at a 33% discount to our quantitative fair value estimate of $37.88 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's profitability increases our estimated valuation. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of 11.0%, which sits in the top 20% compared with global peers. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are undervalued.

The company's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to EBITDA ratio of 4.2, a core component of valuation, sits in the bottom 10% compared with global peers. Relative to the company's EBITDA, the enterprise value of the business is low, which further promotes our favorable price/fair value ratio.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Collegium Pharmaceutical discussion 0 comments

Add a comment